LIVE
Jubilant Pharmova Limited operates as an integrated pharmaceutical company in India, the Americas, Europe, and internationally. It operates through six segments: Radiopharma; Allergy Immunotherapy; Contract Development and Manufacturing Organisation - Sterile Injectables; Generics; Contract Research Development and Manufacturing Organisation; and Proprietary Novel Drugs. The Radiopharma segment offers radiopharmaceuticals products, which are used in the diagnosis and treatment of various diseases, including pulmonary embolism, cancer, coronary artery disease, and others. Its Allergy Immunother. Track Jubilant Pharmova Limited's live NSE:JUBLPHARMA share price ₹933.40 (-0.19%), market cap ₹₹148B, P/E 37.2. MarketRipple's AI analysis covers the investment thesis, ripple-chain impact, and Healthcare sector outlook for JUBLPHARMA — real-time NSE India stock intelligence.
Open
₹936.00
High
₹944.45
Low
₹930.20
Prev. Close
₹935.15
52W High
₹1,184.80
52W Low
₹786.05
Jubilant Pharmova Limited operates as an integrated pharmaceutical company in India, the Americas, Europe, and internationally. It operates through six segments: Radiopharma; Allergy Immunotherapy; Contract Development and Manufacturing Organisation - Sterile Injectables; Generics; Contract Research Development and Manufacturing Organisation; and Proprietary Novel Drugs. The Radiopharma segment offers radiopharmaceuticals products, which are used in the diagnosis and treatment of various diseases, including pulmonary embolism, cancer, coronary artery disease, and others. Its Allergy Immunother
Key Takeaway
Jubilant Pharmova Limited is rated none with a P/E of 37.2x — understand the valuation context before sizing a position.
★ Recommended
Ask AI: Is Jubilant Pharmova Limited fairly valued right now?
Because a P/E of 37.2x needs to be compared against sector peers and growth expectations to be meaningful.
Continue Research
View events affecting Jubilant Pharmova Limited
Because the investment case must account for macro and company-specific developments — events reveal the 'why' behind price moves.
Trace sector ripple effects
Because Healthcare moves create upstream and downstream implications that affect the entire thesis.
Intelligence Path
Growth
Govt Exposure
Policy Dependence
Execution Quality
News Sensitivity
Debt Strength
2,272 Cr
Revenue
119 Cr
Net Profit
6%
ROE
0%
ROCE
25.06
EPS
| ₹ in Crore | FY23 | FY24 | FY25 | FY26 | TTM |
|---|---|---|---|---|---|
| Revenue | 6,219 | 6,645 | 7,192 | 8,225 | 8,183 |
| Net Profit | -61 | 77 | 839 | 398 | 432 |
| ROE (%) | — | — | — | 6.0% | 6.0% |
| EPS (₹) | — | — | — | 25.06 | 25.06 |
| Debt/Equity | — | — | — | 50.9 | 50.9 |